clinical
trials
bivalent
new
jersey
victoria
influenza
vaccines
high
risk
children
various
doses
two
whole
virus
one
split
product
bivalent
influenza
new
jersey
victoria
vaccines
administered
children
aged
six
years
statistically
significant
differences
either
reactivity
humoral
antibody
response
among
children
seven
chronic
disease
categories
healthy
children
whole
virus
vaccines
associated
unacceptably
high
rates
reaction
given
sufficiently
antigenic
initial
doses
relatively
nonreactive
used
booster
immunization
split
product
vaccines
reactive
placebo
vaccine
preparations
induced
adequate
seroconversion
rates
protective
titers
antibody
victoria
virus
one
dose
new
jersey
virus
two
doses
